Lin RY, et al. - Given the usefulness of intravenous mepolizumab use in non-asthma eosinophilic disorders, researchers investigated whether subcutaneous asthma dosing of the drug for eosinophilic pneumonia is efficacious, by analyzing the case of a middle-aged female who was treated with omalizumab for eosinophilic pneumonia for 1 year starting in 2015 with no improvement in symptoms. She was started on mepolizumab 100 mg subcutaneously every 4 weeks in 2016. She experienced symptomatic improvement and had reduced oxygen and systemic corticosteroid needs. Marked improvement was evident on a chest CT performed in February 2018 vs a study in 2016. Also, interval spirometric improvements were reported. Before and during mepolizumab therapy, the observed peripheral blood eosinophils/mm³ were 237 and 10, respectively. Overall, experts concluded that asthma-dosed mepolizumab may elicit a response in parenchymal eosinophilic lung disease. A possible benefit of mepolizumab treatment on attenuating eosinophils not only in airways, but also in lung parenchyma, was suggested over omalizumab treatment in asthma cases with suspected concomitant interstitial disease.